$LNAI

Lunai Bioworks (Nasdaq: LNAI) said it signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics to develop precision neuroscience programs for Parkinson’s disease. Lunai’s BioSymetrics subsidiary published a white paper using the PPMI dataset to identify Parkinson’s subtypes and proteomic signatures. The companies target an initial data readout in 1H 2027.

Lunai Bioworks (Nasdaq: LNAI) said it filed a First Amended Complaint naming 10 defendants, including three FINRA broker dealers, in a naked short selling fraud suit. The company alleges 29.6 million failed-to-deliver shares and that failures to deliver exceeded 80% of shares outstanding from Nov 2025 to May 2026, citing a March 17 trade volume 15.3 times shares outstanding. It seeks treble damages under RICO and other relief.

uniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.

Lunai Bioworks Inc. (LNAI) shares rose 56.77% to $4.46 on Wednesday after the company sent a shareholder letter detailing progress in its AI-driven biodefense and precision neurology businesses. The update cited its first revenue-generating multi-year U.S. government defense contract, expansion of the Pathfinder Consortium, neurology collaborations, and plans to pursue legal action over alleged naked short-selling. Volume was 19.41M vs 1.78M average.

Lunai Bioworks (NASDAQ: LNAI) said its CEO letter highlights progress in AI-enabled biodefense and precision neurology. In April 2026, it secured a multi-year, revenue-generating defense collaboration with BioSymetrics for chemical threat assessment. It also cites the Pathfinder Consortium with major universities and a $1.85 million Phase I/II STTR grant. The letter adds that it filed suit in May 2026 over alleged naked short selling, citing 29.6 million shares failing to deliver.

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

Lunai Bioworks announced it completed a $20 million preferred stock issuance to acquire intellectual property related to CNS delivery and neurotherapeutics. This acquisition adds two new methods to bypass the blood-brain barrier: a prodrug system and a nose-to-brain pathway, bolstering its programs for Alzheimer's and other neurological conditions. The company believes this transaction will also help it meet Nasdaq's minimum stockholder equity requirements.

Lunai Bioworks acquired Neurobridge IP Holdings, a company whose sole assets are a multi-jurisdictional patent portfolio for Alzheimer’s disease and neurological disorders, by issuing $20 million in Series B Convertible Preferred Stock. This transaction aims to help Lunai Bioworks meet Nasdaq's $2.5 million stockholders' equity requirement. The company simultaneously pursues a reverse stock split to address the minimum bid price compliance.

Lunai Bioworks has postponed its Special Meeting of Stockholders from May 4, 2026, to May 8, 2026, to allow more time for shareholders to vote and to ensure a quorum. The delay also aims to comply with broker voting rules under NYSE Rule 452, which were affected by the proxy material distribution timeline. The meeting will address critical proposals, including a proposed reverse stock split, essential for the company's continued Nasdaq listing.

Lunai Bioworks, an AI-powered biotechnology company, has identified three clinically relevant Parkinson's disease subtypes and prioritized drug targets. This breakthrough, utilizing their Augusta Platform and data from The Michael J. Fox Foundation's PPMI study, is aimed at accelerating proof-of-concept programs and enabling strategic co-development partnerships in the growing $13 billion Parkinson's market. The findings are expected to improve trial success rates and accelerate therapeutic development through a more precise, subtype-specific approach.